// App-Quantinova.ai

512 : Efficacy Response to Baricitinib Based on Baseline Characteristics in Patients Who Are Inadequate Responders to Conventional DMARD

Researchers

Presenter

  • Maxime Dougados

Principal Investigators

  • Terence P. Rooney

  • Li Xie

  • Rena Klar

  • Christina L. Dickson

  • Ana Pinto Correia

  • Yoshiya Tanaka

  • Michael Schiff

  • Edward C. Keystone

Medical Centers

  • Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France

  • Eli Lilly and Company, Indianapolis, IN

  • Quintiles IMS Holdings, Inc., Durham, NC

  • The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan

  • University of Colorado Denver, Greenwood Village, CO

  • University of Toronto, Toronto, ON, Canada

Locations

  • France

  • United States

  • Japan

  • Canada

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved